MedTrace Logo

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

NCT01817452 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-02-26

No results posted yet for this study

Summary

Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without chemotherapy backbone within the ADAPT trial.

Conditions

Interventions

DRUG

Trastuzumab

DRUG

Pertuzumab

DRUG

Paclitaxel

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • West German Study Group

    lead OTHER

Principal Investigators

  • Nadia Harbeck, Prof. Dr. · Breast Center of the University of Munich (LMU), Universitätsfrauenklinik Großhadern, Munich, Germany

  • Ulrike Nitz, Prof. Dr. · Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2025-01-15
Completion
2025-01-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01817452 on ClinicalTrials.gov